Drug therapy and hyperprolactinaemia

Adverse Drug Reaction Bulletin

Volumn , Issue 190, 1998, Pages 723-726

  Cohen, Mark A ^a   Davies, Peter H ^a  

^a Sandwell Healthcare NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ATENOLOL; BENZODIAZEPINE; BUTYROPHENONE; CLOZAPINE; DIAZEPAM; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GONADORELIN AGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PAROXETINE; PHENOTHIAZINE; PROGESTERONE; PROLACTIN; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIOXANTHENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

AGRANULOCYTOSIS; AMENORRHEA; ARTICLE; CLINICAL FEATURE; DRUG CHOICE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; PATIENT MONITORING; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

EID: 0031858748     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-199806000-00001     Document Type: Article

References (56)

1. Veldhuis JD, Johnson L. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its tem poral coupling with luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1988; 67: 116
2. Ben-Jonathan N, Dopamin: a prolactin-inhibiting hormone. Endocrine Reviews 1985; 6: 564-89.
3. Nikolics K, Mason AJ, Szonyi E, Ramachandran J, Seeburg PH. A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 1985; 316: 511-17.
4. Molitch ME Pathologic hyperprolactinemia. Endocrinology and Metabolism Clinics of North America 1992; 21: 877-901.
5. Molitch ME Prolactin. In: Melmed S, ed. The Pituitary. Boston* Blackwell Scientific Publications, 1993.
6. Lopez F, Gonzalez D, Aguilar E Possible direct effect of serotonin on pituitary prolactin secretion: in vivo and in vitro studies. Hormone Research 1987; 25: 160-70.
7. Aguilar E, Ranchal A, Tena-Sempere M, Pinilla L. Serotoninergic control of prolactin secretion in prepubertal male rats European Journal of Endocrinology 1994; 131: 547-54.
8. Johnston CA, Negro-Vilar A. Maturation of the prolactin and proopiomelanocortin- derived peptide responses to ether stress and morphine neurochemical analysis Endocrinology 1986; 118: 797-804
9. Vance ML, Thorner MO Prolactin: hyperprolactinemic syndrome and management In: DeGroot LJ, ed Endocrinology Philadelphia: W B Saunders Company, 1989; 408-18
10. Corenblum B Asymptomatic hyperprolactinemia resulting from macroprolactinemia. Fertility and Sterility 1990; 53: 165-7
11. Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. American Journal of Obstetrics and Gynecology 1977; 129: 454-6
12. Stewart PM, Maheshwaran S, Griffith J, et al. Pituitary imaging is essential for women with moderate hyperprolactinaemia. British Medical Journal 1993; 306: 307-8.
13. Daniels GH, Martin JB. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus In. Braunwald E, Isselbacher KJ, Petersdorf RG, et al, eds. Harrison's principles of internal medicine New York: McGraw-Hill Inc. 1991, 1694-1718
14. Walsh JP, Bhagat CI, Pullan PT, Rampono JG. Drug-induced hyperprolactinaemia. Medical Journal of Australia 1994; 161: 343-4.
15. Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 1980; 5: 121-37.
16. Marken PA, Haykal RF, Fisher JN. Management of psychotropic- induced hyperprolactinemia. Clinical Pharmacy 1992; 11: 851-6.
17. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry 1979; 136: 1550-5.
18. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S. Clozapine: plasma levels and prolactin response Psychopharmacology 1981; 73: 184-7.
19. Meltzer HY, Busch DA, Fang VS Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Research 1983; 9: 271-83.
20. Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL. Attenuation of antipsychotic-induced hyperprolactinaemia with clozapine. Journal of Child and Adolescent Psychopharmacology. 1997; 7: 65-9.
21. Hell K, Wernze H. Drug-induced changes in prolactin secretion. Clinical implications Medical Toxicology and Adverse Drug Experience 1988; 3: 463-98
22. West Midlands Centre for Adverse Drug Reaction Reporting, 1996 Personal Communication
23. Zaccaria M, Giordano G, Ragazi E, Campanella N, Marchesi GF, Nardi B Lack of effect of IM diazepam administration on hGH and hPRL secretion in normal and acromegalic subjects. Journal of Endocrinological Investigation 1985; 8: 157-70
24. Tormey WP, Dolphin C, Darragh AS. The effects of diazepam on sleep, and on the nocturnal release of growth hormone, prolactin, ACTH and cortisol. British Journal Clinical of Pharmacology 1979; 8: 90-2.
25. Beary MD, Lacey JH, Bhat AV The neuroendocrine impact of 3-hydroxy-diazepam (temazepam) in women Psychopharmacology 1983; 79: 295-7
26. Copinschi C, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Effects of the short-acting benzodiazepine triazolam, taken at bedtime, on circadian and sleep-related hormonal profiles in normal men. Sleep 1990; 13: 232-44.
27. Copinschi G, Akseki E, Moreno-Reyes R, et al. Effects of bedtime administration of Zolpidem on cireadian and sleep-related hormonal profiles in normal women. Sleep 1995; 18: 417-24.
28. Judd SJ, Lazarus L, Smythe G. Prolactin secretion by metoclopramide in man. Journal of Clinical Endocrinology and Metabolism 1976; 43: 313-17.
29. Perez-Lopez FR, Abos MD Pituitary hormonal response to the orthopramides clebopride, bromopride, metoclopramide and sulpiride. Fertility and Sterility 1982; 37: 445-8.
30. Camanni F, Genazanni AR, Massara F, La Rosa R, Cocchi C, Muller EE. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology 1980; 30: 2-6.
31. Franks S, Jacobs HS, Hull MGR. The oral contraceptive and hyperprolactinemia amenorrhea. In: Cammani F, Muller EE, eds. Pituitary hyperfunction, physiopathology and clinical aspects. New York: Raven Press, 1984; 175-8.
32. Ehrinpreis MN, Dhar R, Narula A. Cimetidine induced galactorrhea. American Journal of Gastroenterology 1989; 84: 563-5.
33. Carlson HE, Ippoliti AF, Swerdloff RS. Endocrine effects of acute and chronic cimetidine administration. Digestive Diseases and Sciences 1981; 26: 428-32
34. Lee PA, Kelly MR, Wallin JD. Increased prolactin levels during reserpine treatment of hypertensive patients. Journal of the American Medical Association 1976; 235: 2316-17.
35. Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Archives of Internal Medicine 1972; 130: 349-54.
36. McNabb WR, Brooks BA, Noormohammed F, et al. The effect of enalapril on serum prolactin British Journal of Clinical Pharmacology 1983; 15: 752-4.
37. Struthers AD, Millar JA, Beastall GH, McIntosh WB, Reid JL. Calcium antagonists and hormone release: effect of nifedipine and luteinizing hormone-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release. Journal of Clinical Endocrinology and Metabolism 1983; 56: 401-4.
38. Teba L, Smailer S, Taylor HC. Effect of nifedipine on TRH stimulation of TSH and PRL release by the pituitary gland. Metabolism. Clinical and Experimental 1985; 34: 161-3
39. Maestri E, Camellini L, Rossi C, Bordonali C, Bellodi G, Gnudi A. Effects of five days verapamil administration on serum GH and PRL levels Hormone Metabolic Research 1985; 17: 482.
40. Romeo JH, Dombrowski R, Kwak YS, Fuehrer S, Aron DC. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clinical Endocrinology. 1996; 45: 571-5.
41. Kelley SR, Kamal TJ, Molitch ME. Mechanism of verapamil calcium blockade-induced hyperprolactinemia. American Journal of Physiology 1996; 270: E96-100
42. Lee S Hyperprolactinemia, galactorrhea and atenolol Annals of Internal Medicine 1992; 116: 522.
43. Matzkin H, Kaver I, Lewyshon O, Ayalon D, Braf Z. The role of increased prolactin levels under GnRH analogue treatment in advanced prostatic carcinoma. Cancer 1988; 61: 2187-91.
44. Siegal YI, Korczak D, Lindner A. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. European Urology 1991; 19: 16-18.
45. Kauschansky A, Yeshaya A, Nussinovitch M, Ben-Rafael Z, Frydman M Hyperprolactinemia after treatment of long-acting gonadotropin-releasing hormone analogue Decapeptyl in girls with central precocious puberty. Fertility and Sterility 1995; 64: 285-7.
46. Herbert DC, Rennels EG. Effect of synthetic luteinizing hormone releasing hormone on prolactin secretion from clonal pituitary cells. Biochemical and Biophysical Research Communications 1977; 79: 133-8.
47. Klibanski A, Neer RM, Beitins IZ, Ridgeway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women New England Journal of Medicine 1980; 303: 1511-14.
48. Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. Journal of Clinical Endocrinology Metabolism 1983; 56: 1120-3.
49. Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea British Journal of Psychiatry 1975; 126: 285-8.
50. Shenoy RS, Ettigi R, Johnson CH Bromocriptine in the treatment of galactorrhea caused by haloperidol: a case study. Journal of Clinical Psychopharmacology 1983; 3: 137-8.
51. Matsuoka I, Nakai T, Miyaki M, Hirai M, Ikawa G. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Japanese Journal of Psychiatry and Neurology 1986; 40: 639-46.
52. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine 1994; 331: 904-9.
53. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. Journal of Clinical Psychopharmacology 1987; 7: 91-5.
54. Siever LJ. The effect of amantadine on prolactin levels and galactorrhea in neuroleptic-treated patients. Journal of Clinical Psychopharmacology 1981; 1: 2-7.
55. Dorevitch A, Aronzon R, Stark M. Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstetricia et Gynecologica Scandinavica 1991; 70: 375-6.
56. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? Journal of Reproductive Medicine 1992; 37: 737-40.